Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 13/20 | 0.37 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | TOP1 | P11387 | 1/20 | 0.35 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.34 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.34 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.34 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8192109 | 0.94 | PDPK1 (0.38) | PTGESKLKB1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL13035094 | 0.87 | KDM4E (0.37) | PTGESKLKB1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL13035259 | 0.87 | MT-CO2 (0.36) | MT-CO2KLKB1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL13035258 | 0.86 | KDM4E (0.35) | KLKB1GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL13035041 | 0.85 | HTT (0.45) | MAPK1 | |
| SCHEMBL13035102 | 0.84 | MAPK8 (0.45) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL8192308 | 0.84 | CYP2C9 (0.39) | MAPK1KLKB1 | |
| SCHEMBL8196409 | 0.84 | CYP2C9 (0.39) | MAPK1KLKB1 | |
| SCHEMBL13035032 | 0.83 | PIK3CA (0.46) | KLKB1PIK3CA | |
| SCHEMBL8197199 | 0.83 | TNKS (0.39) | MAPK1KLKB1GUCY1B2GUCY1A2GUCY1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | PTGES 2605/4885MAPK1 1/4885MT-CO2 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.